In airway inflammation, Phase 1 and 2 clinical trials using an anti-IL-33 mAb, itepekimab, in patients with moderate to severe asthma showed decreased blood eosinophil levels and improved lung function, suggesting that IL-33 may be a promising molecular target for the treatment of allergic asthma [158,159,160]. This evidence concerns the gene IL33 and allergic asthma.